Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

ImmunoCellular Therapeutics Ltd Company Profile (NASDAQ:IMUC)

Consensus Ratings for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $2.75 (227.38% upside)

Analysts' Ratings History for ImmunoCellular Therapeutics Ltd (NASDAQ:IMUC)
Show:
DateFirmActionRatingPrice TargetDetailsShare
6/2/2014Roth CapitalUpgradeNeutral -> Buy$2.00 -> $3.00ViewTweet This Rating  Share This Rating on StockTwits
6/2/2014Maxim GroupLower Price TargetBuy$12.00 -> $4.00ViewTweet This Rating  Share This Rating on StockTwits
1/13/2014Roth CapitalReiterated RatingNeutralViewTweet This Rating  Share This Rating on StockTwits
12/12/2013Summer StreetReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
12/12/2013Roth CapitalDowngradeBuy -> NeutralViewTweet This Rating  Share This Rating on StockTwits
12/12/2013MLV & Co DowngradeBuy -> Hold$6.00 -> $1.25ViewTweet This Rating  Share This Rating on StockTwits
11/25/2013Roth CapitalReiterated RatingBuyViewTweet This Rating  Share This Rating on StockTwits
8/29/2013Lazard Capital MarketsInitiated CoverageBuy$5.00ViewTweet This Rating  Share This Rating on StockTwits
6/7/2013MLV & Co Boost Price Target$5.00 -> $6.00ViewTweet This Rating  Share This Rating on StockTwits
3/6/2013MLV & Co Boost Price TargetBuy$3.50 -> $5.00ViewTweet This Rating  Share This Rating on StockTwits
1/3/2013Roth CapitalInitiated CoverageBuy$6.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/2/2012 forward)
Discuss ImmunoCellular Therapeutics Ltd